<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00164411</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NIP-3669</org_study_id>
    <nct_id>NCT00164411</nct_id>
  </id_info>
  <brief_title>Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine</brief_title>
  <official_title>Pneumococcal Conjugate Vaccine (Prevnar; Wyeth) With Pneumococcal Polysaccharide Vaccine (23-valent) and Tetanus/Diphtheria Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn whether or not giving a tetanus/diphtheria vaccination&#xD;
      (&quot;tetanus shot&quot;) before giving pneumococcal vaccine makes the pneumococcal vaccine more&#xD;
      effective without causing too many side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The only vaccine licensed in the United States for protecting adults against pneumococcal&#xD;
      disease (PPV23) protects against invasive disease in observational studies but has generally&#xD;
      been poorly effective against pneumonia or all-cause mortality in randomized clinical trials.&#xD;
      Another vaccine containing seven polysaccharide antigens conjugated to diphtheria toxoid&#xD;
      (PCV7) is licensed for children and under investigation in adults.&#xD;
&#xD;
      In this pilot study, we are comparing the safety and immunogenicity of three immunization&#xD;
      schedules in adults:&#xD;
&#xD;
        -  Td vaccine, 2-week interval, PCV7, 4-month interval, PPV23&#xD;
&#xD;
        -  PCV7, 4-month interval, PPV23&#xD;
&#xD;
        -  PPV23&#xD;
&#xD;
      We aim to:&#xD;
&#xD;
        -  compare the safety profiles of pneumococcal vaccines given on each of the three&#xD;
           schedules&#xD;
&#xD;
        -  compare serotype-specific ELISA antibody response to pneumococcal antigens given on each&#xD;
           of the three schedules&#xD;
&#xD;
        -  compare functional serotype-specific antibody responses to pneumococcal antigens given&#xD;
           on each of the three schedules&#xD;
&#xD;
        -  study the influence of diphtheria antibody levels at the time of pneumococcal conjugate&#xD;
           vaccine administration on the magnitude of the immune response to pneumococcal antigens&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date>March 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ELISA for S. pneumoniae antibody 2 months after receiving PPV23</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional S. pneumoniae antibody 2 months after receiving PPV23</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events following vaccination from entry to 2 months after receiving last vaccination</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Pneumococcal Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetanus-diphtheria toxoids (Td)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7-valent pneumococcal conjugate vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>23-valent polysaccharide vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in any other investigational clinical trials except purely observational&#xD;
             studies within 4 weeks prior to study start&#xD;
&#xD;
          -  Any vaccination within 2 weeks prior to first study vaccine&#xD;
&#xD;
          -  Evidence of systemic or local infection within one week prior to first study vaccine&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  Receipt of a pneumococcal or Td vaccine within 5 years&#xD;
&#xD;
          -  Current receipt of therapy for neoplastic disease&#xD;
&#xD;
          -  Current receipt of immunosuppressive therapy&#xD;
&#xD;
          -  Terminal illness withlife expectancy less than 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry L Keyserling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>March 13, 2012</last_update_submitted>
  <last_update_submitted_qc>March 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2012</last_update_posted>
  <keyword>Diptheria-Tetanus vaccine</keyword>
  <keyword>Pneumococcal vaccine</keyword>
  <keyword>Adverse events following vaccination</keyword>
  <keyword>Immunization</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

